Race Oncology (ASX:RAC) to trial Bisantrene on various cancers
- Race Oncology (RAC) has updated the market on its activities for the December 2019 quarter
- The company launched a 5-path clinical strategy for its cancer drug called Bisantrene
- Bisantrene is targeting cancers beyond Acute Myeloid Leukaemia (AML), such as ovarian and breast cancer
Race Oncology (ASX:RAC) to trial Bisantrene on various...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
0.000(0.00%) |
Mkt cap ! $257.8M | |||
| Open | High | Low | Value | Volume |
| $1.59 | $1.59 | $1.54 | $88.02K | 56.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22000 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 1100 | 1 |
View Market Depth
| Last trade - 10.55am 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.57 |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| $1.55 | $1.58 | $1.54 | 3168 | ||
| Last updated 11.11am 17/05/2024 ? | |||||
| RAC (ASX) Chart |